表紙
市場調査レポート

慢性骨髄性白血病(CML):パイプライン分析

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192527
出版日 ページ情報 英文 469 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
慢性骨髄性白血病(CML):パイプライン分析 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 469 Pages
概要

慢性骨髄性白血病(CML)とは、骨髄内部の造血細胞が変異して、血液中に侵入していくというがんの一種です。主なリスク要因には、高線量放射線の被爆や年齢・性別などがあります。主な症状として、疲労感や倦怠感、寝汗、体重減少、発熱、骨痛、脾臓の肥大化、下腹部の痛みや膨満感などが挙げられます。主な治療法には、放射線療法や造血細胞移植、化学療法などがあります。

当レポートでは、世界各国での慢性骨髄性白血病(CML)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

慢性骨髄性白血病(CML)の概要

治療薬の開発

  • 慢性骨髄性白血病向けパイプライン製品:概要
  • 慢性骨髄性白血病向けパイプライン製品:比較分析

各企業で開発中の慢性骨髄性白血病治療薬

大学/研究機関で研究中の慢性骨髄性白血病治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

慢性骨髄性白血病治療薬:開発中の製品の一覧(企業別)

慢性骨髄性白血病治療薬:研究中の製品の一覧(大学/研究機関別)

慢性骨髄性白血病治療薬の開発に従事している企業

  • Altor BioScience Corporation
  • Aprea AB
  • arGEN-X BV
  • Ariad Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Baxalta Incorporated
  • Bellicum Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • Biogenomics Limited
  • BioLineRx, Ltd.
  • BioSight Ltd.
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Constellation Pharmaceuticals, Inc.
  • 第一三共
  • Deciphera Pharmaceuticals, LLC
  • エーザイ
  • EpiZyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gamida Cell Ltd.GlycoMimetics, Inc.
  • HEC Pharm Co., Ltd.
  • Hybrigenics S.A.
  • Ilyang Pharmaceutical Co., Ltd
  • Incyte Corporation
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • JW Pharmaceutical Corporation
  • KaloBios Pharmaceuticals, Inc.
  • Karyopharm Therapeutics, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Mirna Therapeutics, Inc.
  • Natco Pharma Limited.
  • Novartis AG
  • 小野薬品工業
  • Oribase Pharma
  • Panther Biotechnology, Inc
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • PharmaEssentia Corporation
  • Polyphor Ltd.
  • Sanofi
  • Selvita S.A.
  • Shenogen Pharma Group Ltd.
  • Stemline Therapeutics, Inc.
  • Sun Pharma Advanced Research Company Ltd
  • 武田薬品工業
  • Targazyme, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Threshold Pharmaceuticals, Inc

慢性骨髄性白血病:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

慢性骨髄性白血病治療薬:パイプライン製品の最新動向

慢性骨髄性白血病治療薬:開発が休止状態の製品

慢性骨髄性白血病治療薬:開発が中止された製品

慢性骨髄性白血病関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7997IDB

Summary

Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
  • The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview
  • Therapeutics Development
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
  • Drug Profiles
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2016
  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corporation, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Aprea AB, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Baxalta Incorporated, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics Limited, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx, Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corporation, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co., Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics S.A., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corporation, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Limited, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Panther Biotechnology, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar, S.A., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corporation, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Polyphor Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sanofi, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita S.A., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Targazyme, Inc., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Recent Pipeline Updates, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..1), H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..2), H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..3), H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..4), H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..5), H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2016
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2016
  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top